Outcomes of Prostate Artery Embolisation in catheterised patients
BAUS ePoster online library. Johnston M. 06/21/21; 319075; p3-7
Disclosure(s): None
Mr. Maximilian Johnston
REGULAR CONTENT
Login now to access Regular content available to all registered users.
Abstract
Discussion Forum (0)
Rate & Comment (0)
Introduction: Prostate artery embolisation (PAE) is an approved treatment for men with lower urinary tract symptoms secondary to benign prostatic hyperplasia (BPH-LUTS). Whilst there is evidence for efficacy of resectional treatments in patients who are unable to void, evidence for efficacy of PAE in this group is scant. This series reports outcomes for PAE in catheterised patients.
Methods: The records of consecutive men with BPH-LUTS who required either an indwelling bladder catheter or clean intermittent self-catheterisation (CISC) and who subsequently underwent PAE were retrospectively reviewed. Basic demographics were collected along with information on the prostate volume and PAE procedure specifics. The primary outcome was catheter/CISC free rates at 3 months. Other reported outcomes include complications, ongoing use/new use of medications and the need for other surgical treatments post-PAE.
Results: 63 men underwent PAE for urinary retention between 2013 and 2020. Of these, 7 underwent a unilateral embolisation for aberrant anatomy. The mean prostate volume was 128ml. 61% of men were free from a catheter/CISC post-treatment. 3 patients subsequently underwent Transurethral Resection of the Prostate following PAE for failure to void. 13 men were free from BPH-LUTS medications.
Conclusions: PAE for catheterised men results in a similar catheter-free rate post procedure to several more invasive BPH treatments. It has a low side-effect profile and gives men with poor health an option to try to become catheter free. PAE should be discussed with men with catheters as a treatment option to allow patient choice.
Methods: The records of consecutive men with BPH-LUTS who required either an indwelling bladder catheter or clean intermittent self-catheterisation (CISC) and who subsequently underwent PAE were retrospectively reviewed. Basic demographics were collected along with information on the prostate volume and PAE procedure specifics. The primary outcome was catheter/CISC free rates at 3 months. Other reported outcomes include complications, ongoing use/new use of medications and the need for other surgical treatments post-PAE.
Results: 63 men underwent PAE for urinary retention between 2013 and 2020. Of these, 7 underwent a unilateral embolisation for aberrant anatomy. The mean prostate volume was 128ml. 61% of men were free from a catheter/CISC post-treatment. 3 patients subsequently underwent Transurethral Resection of the Prostate following PAE for failure to void. 13 men were free from BPH-LUTS medications.
Conclusions: PAE for catheterised men results in a similar catheter-free rate post procedure to several more invasive BPH treatments. It has a low side-effect profile and gives men with poor health an option to try to become catheter free. PAE should be discussed with men with catheters as a treatment option to allow patient choice.
Introduction: Prostate artery embolisation (PAE) is an approved treatment for men with lower urinary tract symptoms secondary to benign prostatic hyperplasia (BPH-LUTS). Whilst there is evidence for efficacy of resectional treatments in patients who are unable to void, evidence for efficacy of PAE in this group is scant. This series reports outcomes for PAE in catheterised patients.
Methods: The records of consecutive men with BPH-LUTS who required either an indwelling bladder catheter or clean intermittent self-catheterisation (CISC) and who subsequently underwent PAE were retrospectively reviewed. Basic demographics were collected along with information on the prostate volume and PAE procedure specifics. The primary outcome was catheter/CISC free rates at 3 months. Other reported outcomes include complications, ongoing use/new use of medications and the need for other surgical treatments post-PAE.
Results: 63 men underwent PAE for urinary retention between 2013 and 2020. Of these, 7 underwent a unilateral embolisation for aberrant anatomy. The mean prostate volume was 128ml. 61% of men were free from a catheter/CISC post-treatment. 3 patients subsequently underwent Transurethral Resection of the Prostate following PAE for failure to void. 13 men were free from BPH-LUTS medications.
Conclusions: PAE for catheterised men results in a similar catheter-free rate post procedure to several more invasive BPH treatments. It has a low side-effect profile and gives men with poor health an option to try to become catheter free. PAE should be discussed with men with catheters as a treatment option to allow patient choice.
Methods: The records of consecutive men with BPH-LUTS who required either an indwelling bladder catheter or clean intermittent self-catheterisation (CISC) and who subsequently underwent PAE were retrospectively reviewed. Basic demographics were collected along with information on the prostate volume and PAE procedure specifics. The primary outcome was catheter/CISC free rates at 3 months. Other reported outcomes include complications, ongoing use/new use of medications and the need for other surgical treatments post-PAE.
Results: 63 men underwent PAE for urinary retention between 2013 and 2020. Of these, 7 underwent a unilateral embolisation for aberrant anatomy. The mean prostate volume was 128ml. 61% of men were free from a catheter/CISC post-treatment. 3 patients subsequently underwent Transurethral Resection of the Prostate following PAE for failure to void. 13 men were free from BPH-LUTS medications.
Conclusions: PAE for catheterised men results in a similar catheter-free rate post procedure to several more invasive BPH treatments. It has a low side-effect profile and gives men with poor health an option to try to become catheter free. PAE should be discussed with men with catheters as a treatment option to allow patient choice.
Code of conduct/disclaimer available in General Terms & Conditions
{{ help_message }}
{{filter}}